The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. | Biotechs will need to be strategic to ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions.

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...